Comparison of recombinant human erythropoietin and darbepoetin alpha in children

Can, Ceren; Emre, Sevinç; Bilge, İlmay; Yılmaz, Alev; Şirin, Aydan

doi:10.1111/ped.12085

Cited by 11 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Table (4) demonstrates the ferrokinetic data of the studied groups. There was a very highly significant increase in the mean hypochromic cell percentage on comparing groups I, II before treatment and II after treatment with group III ( p< 0.0001).…”

Section: Resultsmentioning

confidence: 99%

“…Chronic kidney disease is the gradual, progressive reduction in the glomerular filtration rate (GFR) with deterioration of kidney function and the disease is classified to five stages where the 5 th stage represents the end stage renal failure (1) The cause of anemia of chronic kidney disease (CKD) is mainly due to a decrease in the response to endogenous erythropoietin (EPO) which is produced in the kidney and the liver and stimulates erythropoiesis (2). The erythropoietic stimulating agents (ESAs) as, recombinant human erythropoietin (rHuEPO), epoetinalfa, and darbepoetin alpha; are analogues of the natural hormone erythropoietin (2)(3)(4)(5)(6). These agents are used to manage the anemia of CKD instead of the blood transfusion to decrease the risk of transfusion-related complications with marked improvement in the outcome especially in the end stage of the disease (6, 7).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of Iron Status in Anemic Children with Chronic Kidney Disease

Alzahrani

Nashar

et al. 2013

EJHM

View full text Add to dashboard Cite

Background: Iron deficiency is the commonest cause of resistance to erythropoiesis stimulating agents (ESAs) in dialyzed children treated from anemia of chronic kidney disease (CKD). Aim of the work: This study was conducted in order to evaluate the significance of different biomarkers in assessment of iron status during management of anemic children with CKD. Patients and method: Twenty five children with diagnosis of anemia of chronic kidney disease were enrolled for the study. They were classified into two groups according to their stage of the kidney disease. Group I; included 15 children with anemia of CKD and their Glomerular Filtration Rate (GFR) was 15.5-29.6 ml/min/1.73m 2 (stages; III & IV CKD) and they were managed conservatively. Group II; It included 10 anemic children with end stage renal disease (Stage V CKD, GFR was 6.1-13.7 ml/min/1.73m 2) and they were under regular hemodialysis. Another 10 healthy children with matched age and gender served as control group (group III). Results: The study showed that the hypochromic cell percentage was significantly higher in both groups I and II before treatment when compared to controls (p <0.0001). Serum ferritin showed very high significant elevation in all the studied groups as compared to controls, also group II was highly significant when compared with group I before treatment. Improvement of iron mobilization and metabolism after 8 weeks of therapy with intravenous iron and erythropoietin was evidenced by significant increase in hemoglobin (Hb) level, RBCs and HCT % when comparing the group II patients before and after treatment. Also significant decrease in hypochromic cell percentage and increase in serum ferritin were proved. The sTfR and sTfR/ F indices showed elevation in the post-treatment group. Conclusion: No single biomarker is reliable alone in the assessment and monitoring the iron status in anemic patients with CKD under ESAs therapy. Measurement of hypochromic cell percentage may be simple and reliable method, and sTfR represents a valuable quantitative assay of marrow erythropoietic activity as well as a marker of tissue iron deficiency. However, the sTfR / Ferritin index is considered to be more efficient in anemic patients with CKD for early prediction of functional iron deficiency and is a sensitive tool for follow up of iron status during ESAs therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Assessment of Iron Status in Anemic Children with Chronic Kidney Disease

Alzahrani

Nashar

et al. 2013

EJHM

View full text Add to dashboard Cite

show abstract

“…The introduction of recombinant human erythropoietin (rHuEPO) to the treatment regimen three decades ago revolutionized the therapy and significantly decreased the need for repeated blood transfusions and exposure to the associated risks. Darbopoetin alpha is a reasonable alternative to rHuEPO in the treatment of anemia in pediatric CKD patients, due to its clinical efficacy, convenience of use, patient compliance and tolerability (31).…”

Section: Comorbidity Of Chronic Kidney Diseasementioning

confidence: 99%

How to grow up with chronic kidney disease?

Peco-Antić

2018

CEJP

View full text Add to dashboard Cite

“…1.5 to 2.0 gram of iron is supposed to be lost from the body per year, by the dialyzed patients 7 , so if these patients do not receive exogenous iron, they will have low iron levels in their bodies and ultimately their iron stores will also be exhausted 8 . The recombinant human erythropoietin is synthesized by the recombinant DNA technology which resembles both physiologically and structurally to the natural erythropoietin (EPO) [9][10][11] . Recombinant technology of human erythropoietin has played an enormous role for the past many years for the treatment of CRF patients.…”

Section: Introductionmentioning

confidence: 99%

Comparative Study of Oral versus Intravenous Iron Therapy in Patients of Chronic Renal Failure Receiving Recombinant Human Erythropoietin

2019

J Liaquat Uni Med Health Sci

View full text Add to dashboard Cite

OBJECTIVE: To evaluate the effects of oral and intravenous Iron on serum ferritin and total Iron binding capacity in patients of chronic renal failure receiving recombinant human erythropoietin. METHODOLOGY: This prospective comparative interventional study was conducted in the Department of Pharmacology and Therapeutics LUMHS Jamshoro with the collaboration of Urology Department of Liaquat University Hospital (LUH) Jamshoro and Hyderabad, for the duration of 6 months after approval from research ethics committee of the institute. By using Rao software sampling calculator and after following inclusion and exclusion criteria 80 patients were taken and divided into two groups, Group A (Oral Iron+rHuEPO) & Group B (I/V Iron+rHuEPO). Informed consent was taken from all patients. Serum ferritin & TIBC were done at the beginning and at the end of the six months. Data was analyzed on SPSS version 16.0 (IBM, Incorporation, USA). The continuous variables were analyzed by student's t-test. The significant p-value was taken at ≤ 0.05. RESULTS: Significant statistical improvement was observed in Serum Ferritin and TIBC of both Groups (Group A and Group B). But there is more prominent improvement in serum ferritin and TIBC of Group B (I/V iron + rHuEPO). No adverse effects of iron therapy and erythropoietin therapy were observed in patients of both groups. CONCLUSION: The present study concludes that treatment with I/V Iron + Erythropoietin therapy significantly improves Serum Ferritin and TIBC of CRF patients of Group B who received Intravenous Iron Dextran 2ml diluted in 200ml normal saline twice a month + rHuEPO 2000 IU SC twice a week.

show abstract

Comparison of recombinant human erythropoietin and darbepoetin alpha in children

Abstract: DA is a reasonable alternative to rHuEPO in the treatment of anemia in pediatric CKD patients, due to its clinical efficacy, convenience of use, patient compliance and tolerability.

Cited by 11 publications

References 19 publications

Assessment of Iron Status in Anemic Children with Chronic Kidney Disease

Assessment of Iron Status in Anemic Children with Chronic Kidney Disease

How to grow up with chronic kidney disease?

Comparative Study of Oral versus Intravenous Iron Therapy in Patients of Chronic Renal Failure Receiving Recombinant Human Erythropoietin

Contact Info

Product

Resources

About